GlassScriptPhysician profile
Aarti K Kapur
NPI 1922216902
$4,205.54
in general payments reported to CMS, 2019-2025
26 companies · $670 in 2025
The $670 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $31.72 · 2021: $121 · 2022: $467 · 2023: $1,291 · 2024: $705 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,500 · Travel and Lodging: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,500.23 |
| Travel and Lodging | $165.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $605.56 | 2021-2025 | |
| Alkermes, INC. | $313.14 | 2019-2024 | Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $293.27 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $272.97 | 2019-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $240.61 | 2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $236.27 | 2019-2023 | Uzedy, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $226.10 | 2023 | Andexxa |
| Neurocrine Biosciences, INC. | $194.55 | 2020-2025 | Ingrezza |
| Abbott Laboratories | $165.85 | 2023 | Infinity |
| Acadia Pharmaceuticals INC | $162.41 | 2019-2024 | Nuplazid |
| Vanda Pharmaceuticals INC. | $157.90 | 2023-2024 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $141.68 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $138.65 | 2024-2025 | Spravato |
| Allergan, INC. | $127.30 | 2019 | |
| Mdd US Operations, LLC | $125.00 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $125.00 | 2025 | Brixadi |
| Sunovion Pharmaceuticals INC. | $123.18 | 2019-2021 | |
| Validus Pharmaceuticals LLC | $120.00 | 2019 | |
| Lundbeck LLC | $117.96 | 2019-2025 | Rexulti |
| Biogen, INC. | $100.00 | 2024 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $89.33 | 2020-2025 | Trintellix |
| Tris Pharma INC | $60.05 | 2022-2023 | Dyanavel Xr |
| Tms Neurohealth Centers INC. | $25.97 | 2025 | Tms Neurohealth Centers INC. |
| Noven Therapeutics, LLC | $15.60 | 2023 | Secuado |
| Shire North American Group INC | $15.44 | 2019 | |
| Corium, LLC | $11.75 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aarti Kapur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.